>

MEETINGS / EVENTS

RSS

November 08 - 09 2014, 12:00 AM - 12:00 AM

ASA Quality Meeting 2014

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

>

FDA MEDWATCH ALERTS

October 20, 2014

Lidocaine HCI Injection, USP 10 MG Per ML, 30 ML Single-Dose, Preservative-Free, by Hospira: Recall - Particulate Matter

Summary:

FDA Medwatch Alert 10-20-14

October 16, 2014

FDA MedWatch - LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for Leakage

Summary:

FDA MedWatch LifeCare Flexible Intravenous Solutions by Hospira Inc

October 13, 2014

FDA MedWatch - CareFusion EnVe and ReVel Ventilators: Class 1 Recall - Power Connection Failure

Summary:

FDA MedWatch CareFusion EnVe and ReVel Ventilators

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

Latest Drug Shortage - Phenylephrine

Wednesday, May 04, 2011

American Regent, one of the largest manufacturers of injectable medications is suspending all production of Phenylephrine HCI injection of 10mL, 5mL, and 1mL vials and has no estimate of a release date at this time.

On April 25, 2011, FDA reported that two drug manufacturers  of Phenylephrine (Baxter and Sandoz) are also experiencing a delay in production of the drug as a result of the recent change in market requirements.

Due to American Regent’s suspension of Phenylephrine production, Baxter manufacturer is experiencing a backorder delay on 1 mL and 10mL vials of Phenylephrine HCI injection drug. However, Baxter has accelerated production and anticipates having Phenylephrine available in mid May. Additional lots are scheduled for manufacturing and are anticipated to be available for distribution in the June – July timeframe.

Sandoz is also experiencing a backorder of 10 mL and 5 mL vials of Phenylephrine HCI injection as the current market demand is more than the company’s current inventory can meet. Sandoz anticipates increased product availability by the end of May.

ASA has been informed that Luitpold Pharmaceuticals, the parent company of American Regent Manufacturer, is in the process of developing a plan, in conjunction with the FDA that will allow it to resume manufacturing and distribution of its American Regent Drug products as soon as possible.

 

« Back to Washington Alerts